Literature DB >> 3538853

High plasma cholecystokinin levels in patients with chronic pancreatitis having abdominal pain.

A Funakoshi, I Nakano, H Shinozaki, K Tateishi, T Hamaoka, H Ibayashi.   

Abstract

Plasma cholecystokinin (CCK) responses after ingestion of a test meal in patients with mild chronic pancreatitis having abdominal pain were studied with a radioimmunoassay using the CCK specific antiserum (OAL-656) produced by a novel immunization procedure. Mean concentration of the fasting plasma CCK determined using CCK-8 as a standard was 31.5 +/- 5.8 pg/ml in six patients who had mild impaired exocrine function with pain, and was significantly higher than 10 healthy subjects (9.8 +/- 1.8 pg/ml). In those patients, the ingestion of a liquid test meal led to a peak of 75.1 +/- 25.4 pg/ml at 30 min, and the 120-min integrated CCK response (5427 +/- 1217.3 pg X min/ml) was significantly higher than in healthy subjects (1538 +/- 110.1 pg X min/ml).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3538853

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

Review 1.  Medical Management of Pain in Chronic Pancreatitis.

Authors:  Vikesh K Singh; Asbjørn M Drewes
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

Review 2.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

3.  Plasma CCK levels in patients with pancreatic insufficiency.

Authors:  T Bozkurt; G Adler; I Koop; H Koop; W Türmer; R Arnold
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

4.  Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis.

Authors:  M Sugiyama; Y Atomi; N Wada; A Kuroda; T Muto
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

5.  Colonic mucosal proliferation after pancreaticobiliary diversion in the hamster.

Authors:  M Chu; J F Rehfeld; K Borch
Journal:  Dig Dis Sci       Date:  1993-11       Impact factor: 3.199

6.  No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency.

Authors:  T Nakamura; K Takebe; K Kudoh; M Ishii; K Imamura; H Kikuchi; F Kasai; Y Tandoh; N Yamada; Y Arai
Journal:  Int J Pancreatol       Date:  1995-02

7.  Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers.

Authors:  H Friess; J Kleeff; P Malfertheiner; M W Müller; K Homuth; M W Büchler
Journal:  Int J Pancreatol       Date:  1998-04

8.  Regulation of intestinal concentration of cholecystokinin by bile and/or pancreatic juice.

Authors:  K Miyasaka; A Funakoshi; M Matsumoto; K Kitani
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

9.  Direct, concentration-dependent inhibition by taurocholate of pancreatic exocrine secretion and CCK release in conscious rats.

Authors:  H Tomita; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

10.  Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.

Authors:  N Sazaki; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.